Allied Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	849.51	806.92	720.43	716.75	676.76
Revenue Growth (YoY)	5.28%	12.01%	0.51%	5.91%	9.50%
Cost of Revenue	540.9	548.53	473.99	445.7	418.71
Gross Profit	308.61	258.38	246.44	271.05	258.05
Selling, General & Admin	159.79	144.15	131.64	144.71	120.64
Research & Development	28.43	26.12	26.09	24.56	25.74
Operating Expenses	188.27	170.27	157.73	171.27	146.38
Operating Income	120.34	88.12	88.71	99.78	111.67
Interest Expense	-17.32	-13.96	-12.96	-11.75	-11.25
Interest & Investment Income	22.5	24.67	15.63	5.3	1.65
Currency Exchange Gain (Loss)	36.22	30.92	29.88	88.11	-85.55
Other Non Operating Income (Expenses)	3.24	0.29	1.12	5.01	1.06
EBT Excluding Unusual Items	164.98	130.04	122.38	186.45	17.58
Gain (Loss) on Sale of Assets	-0.86	-	-	-1.59	-
Other Unusual Items	-	-	-	0.17	-
Pretax Income	164.12	130.04	122.38	185.04	17.58
Income Tax Expense	34.67	29.1	24.97	38.29	4.54
Net Income	129.46	100.94	97.41	146.74	13.04
Net Income to Common	129.46	100.94	97.41	146.74	13.04
Net Income Growth	28.25%	3.62%	-33.62%	1025.14%	-83.59%
Shares Outstanding (Basic)	96	96	96	95	95
Shares Outstanding (Diluted)	96	96	96	96	95
Shares Change (YoY)	0.10%	0.37%	0.20%	0.43%	0.05%
EPS (Basic)	1.35	1.05	1.02	1.54	0.14
EPS (Diluted)	1.34	1.05	1.01	1.53	0.14
EPS Growth	27.62%	3.96%	-33.99%	1018.40%	-83.52%
Free Cash Flow	127.62	196.98	89.71	109.62	22.44
Free Cash Flow Per Share	1.32	2.04	0.94	1.14	0.23
Dividend Per Share	1.250	1.000	0.850	1.200	0.500
Dividend Growth	25.00%	17.65%	-29.17%	140.00%	-37.50%
Gross Margin	36.33%	32.02%	34.21%	37.82%	38.13%
Operating Margin	14.16%	10.92%	12.31%	13.92%	16.50%
Profit Margin	15.24%	12.51%	13.52%	20.47%	1.93%
Free Cash Flow Margin	15.02%	24.41%	12.45%	15.29%	3.32%
EBITDA	175.73	144.33	152.38	165.12	170.53
EBITDA Margin	20.69%	17.89%	21.15%	23.04%	25.20%
D&A For EBITDA	55.39	56.21	63.67	65.34	58.86
EBIT	120.34	88.12	88.71	99.78	111.67
EBIT Margin	14.16%	10.92%	12.31%	13.92%	16.50%
Effective Tax Rate	21.12%	22.38%	20.41%	20.70%	25.81%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.